Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China

International Journal of Technology Assessment in Health Care

Volumn 28, Issue 4, 2012, Pages 436-444

  Gao, Lan ^a   Zhao, Fei Li ^b   Li, Shu Chuen ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Cost effectiveness; Cost utility analysis; Glimepiride; Liraglutide; Type 2 diabetes mellitus; UKPDS Outcomes Model

Indexed keywords

CLINICAL TRIAL; COST-EFFECTIVENESS RATIOS; COST-UTILITY ANALYSIS; GLIMEPIRIDE; HEALTH-CARE SYSTEM; LIFE EXPECTANCIES; LIRAGLUTIDE; METFORMINS; TREATMENT EFFECTS; TYPE 2 DIABETES MELLITUS; TYPE-2 DIABETES;

COST EFFECTIVENESS; COSTS; PATIENT TREATMENT;

COST BENEFIT ANALYSIS;

GLIMEPIRIDE; LIRAGLUTIDE; METFORMIN;

ARTICLE; CHINA; COST BENEFIT ANALYSIS; HEALTH CARE SYSTEM; INCIDENCE; LIFE EXPECTANCY; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; QUALITY OF LIFE; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

CHINA; CONFIDENCE INTERVALS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; GLUCAGON-LIKE PEPTIDE 1; HEALTH CARE COSTS; HUMANS; HYPOGLYCEMIC AGENTS; LIFE EXPECTANCY; METFORMIN; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; SULFONYLUREA COMPOUNDS;

EID: 84867534512     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462312000608     Document Type: Article

References (43)

1. Borgstrom F, Johnell O, Kanis J. At what hipfracture risk is it cost-effective to treat? International intervention threshold for the treatment of osteoporosis. Osteoporos Int. 2006;17:1459-1471.
2. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39-47.
3. Chen Z, Zhang S, Yang L, et al. Association between side effects of oral anti-diabetic drugs and self-reported mental health and quality of life among patients with type 2 diabetes. Natl Med J China. 2011;91:229-233. In Chinese
4. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making. 2002;22:340-349.
5. Clarke P, Gray AM, Briggs AH, et al. A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologe. 2004;47:1747-1759.
6. Davies MJ, Chubb BD, Smith IC, Valentine WJ. Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus. Diabet Med. 2012;29:313-320.
7. Dolezal T, Niewada M, Rychna K, Czech M. Long-term cost-effectiveness of liraglutide vs. rosiglitazone in the Czech Republic. In: ISPOR 13th Annual European Congress, 2010, Prague, Czech Republic.
8. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101:515-520.
9. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473-481.
10. Gutzwiller JP, Goke B, Drewe J, et al. Glucagon-like peptide-1: A potent regulator of food intake in humans. Gut. 1999;44:81-86.
11. Ilavska A, Uliciansky V, Wrona W, Lacka J, Czech M. Cost-effectiveness of liraglutide in people with type 2 diabetes in the Slovak Republic. In: ISPOR 13th Annual European Congress, 2010, Prague, Czech Republic.
12. Jia WP, Pang C, Chen L. Epidemiology characteristics of diabetes mel-litus and impaired glucose regulation in a chinese adult population: The shanghai diabetes studies, a cross-sectional 3-year follow-up study in shanghai urban communities. Diabetologia. 2007;50:286-292.
13. Jonsson B. Revealing the cost of Type II diabetes in Europe. Diabetologia. 2002;45:S5-S12.
14. Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: An analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008;31:845-851.
15. Kiberd BA and Jindal KK. Screening to prevent renal failure in insulin dependent diabetic patients: An economic evaluation. BMJ. 1995;311:1595-1599.
16. Lee WC, Conner C, Hammer M. Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States. Clin Ther. 2010;32:1756-1767.
17. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26:268-278.
18. Mu PW, Chen YM, Lu HY, et al. Effects of a combination of oral antidiabetes drugs with basal insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes. Diabetes Metab Res Rev. 2012;28:236-240.
19. Murray CJ, Lauer JA, Hutubessy RC, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: A global and regional analysis on reduction of cardiovascular-disease risk. Lancet. 2003;361:717-725.
20. Naslund E, Gryback P, Backman L, et al. Distal small bowel hormones: Correlation with fasting antroduodenal motility and gastric emptying. Dig Dis Sci. 1998;43:945-952.
21. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32:84-90.
22. NICE. NICE recommends liraglutide for type 2 diabetes mellitus. http://www.nice.org.uk/newsroom/pressreleases/2010156liraglutidepressrelease. jsp (accessed Month day, year).
23. NICE. Final Appraisal Determination.Liraglutide for the Treatment of Type 2 Diabetes. http://www.nice.org.uk/nicemedia/live/11895/50663/50663.pdf (accessed 14 January 14, 2011).
24. Niewada M, Wrona W, Czech M, Schubert A, Skrzekowska-Baran I. Long-term cost-effectiveness of liraglutide vs. sulphonylurea in Poland. In: ISPOR 13th Annual European Congress, 2010, Prague, Czech Republic.
25. Palmer JL, Beaudet A, White J, Plun-Favreau J, Smith-Palmer J. Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in China. Adv Ther. 2010;27:814-827.
26. Palmer JL, Gibbs M, Scheijbeler HW, et al. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China. Adv Ther. 2008;25:752-774.
27. Ranganath LR, Beety JM, Morgan LM, et al. Attenuated GLP-1 secretion in obesity: Cause or consequence? Gut. 1996;38:916-919.
28. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): A randomised controlled trial. Diabetologia. 2009;52:2046-2055.
29. Sullivan SD, Alfonso-Cristancho R, Conner C, Hammer M, Blonde L. Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone. Cardiovasc Dia-betol. 2009;8:12.
30. Tang L, Chen X, Chen H. The economic burden of type 2 diabetes mellitus and its complications in the cities of China. Chin Health Econ Mag. 2003;22:21-23. In Chinese.
31. Thomas GN, Critchley JA, Tomlinson B, Cockram CS, Chan JC. Peripheral vascular disease in Type 2 diabetic Chinese patients: Associations with metabolic indices, concomitant vascular disease and genetic factors. Diabet Med. 2003;20:988-995.
32. Turner RC. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) (vol 352, pg 837, 1998). Lancet. 1999;354:602-602.
33. Valentine WJ, Palmer AJ, Lammert M, Langer J, Brandle M. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents. Clin Ther. 2011;33:1698-1712.
34. Valentine WJ, Palmer AJ, Nicklasson L, Cobden D, Roze S. Improving life expectancy and decreasing the incidence of complications associated with type 2 diabetes: A modelling study of HbA1c targets. Int J Clin Pract. 2006;60:1138-1145.
35. WHO. Report on macroeconomics and health: Investing in Health for Economic development. Geneva: World Health Organization; 2001.
36. WHO. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003.
37. WilliamsR, Van GaalL, LucioniC.Assessing the impactofcomplications on the costs of Type II diabetes. Diabetologia. 2002;45:S13-S17.
38. Wu J, Wu JH, Chang J. Long-Term health outcomes of treatment with liraglutide versus glimepriride in Type 2 diabetes patients in asian setting. In: ISPOR 4th Asia-Pacific Conference, 2010, Phuket, Thailand.
39. Xie X, Vondeling H. Cost-utility analysis of intensive blood glucose control with metformin versus usual care in overweight type 2 diabetes mellitus patients in Beijing, P.R. China. Value Health. 2008;11(Suppl 1):S23-32.
40. Xu L, Xie X, Wang S, Wang Y, Jonas JB. Prevalence of diabetes mellitus in China. Exp Clin Endocrinol Diabetes. 2008;116:69-70.
41. Yang W, Chen L, Ji Q, et al. Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: A 16-week, randomized, double-blind, active control trial. Diabetes Obes Metab. 2011;13:81-88.
42. Zhou X, Ji L, Luo Y, et al. Organization and delivery of care performance of HbA1c for detecting newly diagnoseddiabetes and prediabetes in Chinese communities living in Beijing. Diabet Med. 2009;26: 1262.
43. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with met-formin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009;32:1224-1230.